Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

被引：40
|
作者：
Bethel, M. Angelyn
Mentz, Robert J.
Merrill, Peter
Buse, John B.
Chan, Juliana C.
Goodman, Shaun G.
Iqbal, Nayyar
Jakuboniene, Neli
Katona, Brian G.
Lokhnygina, Yuliya
Lopes, Renato D.
Maggioni, Aldo P.
Ohman, Peter K.
Poulter, Neil R.
Ramachandran, Ambady
Tankova, Tsvetalina
Zinman, Bernard
Hernandez, Adrian F.
Holman, Rury R.
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-522-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
    Holman, Rury R.
    Bethel, Mary Angelyn
    George, Jyothis
    Sourij, Harald
    Doran, Zoe
    Keenan, Joanne
    Khurmi, Nardev S.
    Mentz, Robert J.
    Oulhaj, Abderrahim
    Buse, John B.
    Chan, Juliana C.
    Iqbal, Nayyar
    Kundu, Sudeep
    Maggioni, Aldo P.
    Marso, Steven P.
    Oehman, Peter
    Pencina, Cmichael J.
    Poulter, Neil
    Porter, Lisa E.
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    AMERICAN HEART JOURNAL, 2016, 174 : 103 - 110
  • [2] Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Hernandez, A. F.
    Bethel, M. A.
    Bakris, G. L.
    Merrill, P.
    Gustavson, S. M.
    Katona, B. G.
    Ohman, P.
    Lokhnygina, Y.
    Mentz, R. J.
    Holman, R. R.
    DIABETOLOGIA, 2018, 61 : S38 - S38
  • [3] Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Mentz, Robert
    Bethel, M. Angelyn
    Gustavson, Stephanie
    Thompson, Vivian
    Buse, John B.
    Chan, Juliana
    Maggioni, Aldo P.
    Marso, Steven P.
    Ohman, Peter
    Poulter, Neil
    Ramachandran, Ambady
    Zinman, Bernard
    Iqbal, Nayyar
    Hernandez, Adrian F.
    Holman, Rury R.
    DIABETES, 2016, 65 : A271 - A271
  • [4] Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Mentz, Robert J.
    Bethel, M. Angelyn
    Gustavson, Stephanie
    Thompson, Vivian P.
    Pagidipati, Neha J.
    Buse, John B.
    Chan, Juliana C.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Marso, Steve P.
    Ohman, Peter
    Poulter, Neil
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    Holman, Rury R.
    AMERICAN HEART JOURNAL, 2017, 187 : 1 - 9
  • [5] Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Green, Jennifer B.
    Merrill, Peter
    Lokhnygina, Yuliya
    Mentz, Robert J.
    Alfredsson, Joakim
    Holman, Rury R.
    EXSCEL Study Grp
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1473 - 1484
  • [6] Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Timothy M. E. Davis
    Anna Giczewska
    Yuliya Lokhnygina
    Robert J. Mentz
    Naveed Sattar
    Rury R. Holman
    Cardiovascular Diabetology, 21
  • [7] Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Davis, Timothy M. E.
    Giczewska, Anna
    Lokhnygina, Yuliya
    Mentz, Robert J.
    Sattar, Naveed
    Holman, Rury R.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [8] Changes in serum calcitonin concentrations and incidence of adjudicated medullary thyroid carcinoma in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Katona, B.
    Bethel, M. A.
    Patel, R.
    Thompson, V. P.
    Gustavson, S. M.
    Ohman, P.
    Iqbal, N.
    Buse, J. B.
    Hernandez, A. F.
    Holman, R. R.
    DIABETOLOGIA, 2018, 61 : S376 - S376
  • [9] Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Bethel, M. Angelyn
    Patel, Rishi A.
    Thompson, Vivian P.
    Merrill, Peter
    Reed, Shelby D.
    Li, Yanhong
    Ahmadi, Sara
    Katona, Brian G.
    Gustavson, Stephanie M.
    Ohman, Peter
    Iqbal, Nayyar
    Gagel, Robert F.
    Hernandez, Adrian F.
    Buse, John B.
    Holman, Rury R.
    DIABETES CARE, 2019, 42 (06) : 1075 - 1080
  • [10] Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL
    Clegg, L. E.
    Penland, R. C.
    Bachina, S.
    Boulton, D. W.
    Thuresson, M.
    Heerspink, H. J. L.
    Gustavson, S.
    Sjostrom, C. D.
    Ruggles, J.
    Hernandez, A. F.
    Buse, J. B.
    Mentz, R. J.
    Holman, R. R.
    DIABETOLOGIA, 2019, 62 : S4 - S5
12345